丝裂霉素膀胱灌注热化疗治疗T<sub>1</sub>G<sub>3</sub>膀胱尿路上皮癌的疗效分析

赵振华; 赵国平; 郑东升; 陈仕杰; 李岱; 林淑贞

doi:10.13201/j.issn.1001-1420.2020.02.003

丝裂霉素膀胱灌注热化疗治疗T₁G₃膀胱尿路上皮癌的疗效分析

- 南方医科大学附属江门医院泌尿外科(广东江门, 529000)
基金项目:
广东省江门市科技计划项目(No:江科2018124)

详细信息

通讯作者: 赵振华,E-mail:zzh2012@126.com

中图分类号: R737.14

收稿日期: 2019-02-14

Analysis of intravesical mitomycin C combined with hyperthermia to treat T₁G₃ bladder urothelial carcinoma

- Department of Urology, Jiangmen Hospital Affiliated to Southern Medical University, Jiangmen, Guangdong, 529000, China

More Information

Corresponding author: ZHAO Zhenhua, E-mail: zzh2012@126.com

Received Date: 14 February 2019

摘要

摘要: 目的:探讨丝裂霉素膀胱灌注热化疗治疗T₁G₃膀胱尿路上皮癌的疗效及安全性。方法:76例原发性或复发性T₁G₃膀胱尿路上皮癌患者,均行经尿道膀胱肿瘤电切术,40例患者术后接受单独丝裂霉素进行膀胱灌注治疗,36例患者接受术后予丝裂霉素进行膀胱灌注热化疗。随访时间>24个月。分析两种治疗方法的无复发生存期和无进展生存期。结果:在76例患者中,单纯膀胱灌注化疗组肿瘤复发率及进展率分别为35%及22.5%,膀胱灌注热化疗组复发率及进展率分别为13.9%和5.6%。两组比较差异有统计学意义。(P=0.034及P=0.036)。Kaplan-Meier分析显示两种治疗方法无复发生存率及无进展生存率差异有统计学意义(P=0.027及P=0.047)。结论:T₁G₃膀胱尿路上皮癌TURBT术后予MMC膀胱灌注热化疗治疗是安全,有效的。能有效降低T₁G₃膀胱尿路上皮癌术后复发和肿瘤进展风险。
- 膀胱癌 /
- 膀胱灌注化疗 /
- 热疗 /
- 复发 /
- 进展
Abstract: Objective: To investigate the efficacy and safety of intravesical mitomycin C(MMC) combined with hyperthermia for patients with T₁G₃ bladder urothelial carcinoma after transurethral resection of the bladder tumor(TURBT). Method: Seventy-six patients suffering from primary or recurrent T₁G₃ transitional cell carcinoma of the bladder underwent TURBT. Forty patients received intravesical chemotherapy alone, whereas 36 patients underwent chemotherapy of MMC combined with hyperthermia. Minimum follow-up period was 24 months. Recurrence-free survival and progression-free survival of the two chemotherapy strategies following TURBT were analyzed. Result: Of the 76 patients completed the study were analyzed statistically valid. The tumor recurrence rate was 35% for patients who received intravesical chemotherapy alone after TURBT, compared with 13.9% for patients who received intravesical chemotherapy of MMC combined with hyperthermia after TURBT. The progression rate was 22.5% for patients who underwent intravesical chemotherapy alone and 5.6% for patients who underwent the combined hyperthermia. Kaplan-Meier curves showed significant difference in recurrence-free survival and progression-free survival between the two treatment strategies, with a log-rank P-value of 0.027 and 0.047, respectively.Conclusion: It can be a safe and effective treatment option after TURBT in patients with T₁G₃ bladder urothelial carcinoma for intravesical chemotherapy of MMC combined with hyperthermia. It is a good method to prevent the recurrence and reduce the risk of disease progression.
- bladder cancer /
- intravesical chemotherapy /
- hyperthermia /
- recurrence /
- progression

HTML全文

参考文献(16)

[1]	Milla P,Fiorito C,Soria F,et al.Intravesical thermo-chemotherapy based on conductive heat:a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients[J].Cancer Chemother Pharmacol,2014,73(3):503-509.
[2]	Abern MR,Owusu RA,Anderson MR,et al.Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer:a systematic review and meta-analysis[J].J Natl Compr Canc Netw,2013,11(4):477-484.
[3]	Lammers R J,Witjes J A,Inman B A,et al.The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer:a systematic review[J].Eur Urol,2011,60(1):81-93.
[4]	van der Heijden AG,Jansen CF,Verhaegh G,et al.The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines[J].Eur Urol,2004,46(5):670-674.
[5]	Halachmi S,Moskovitz B,Maffezzini M,et al.Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder[J].Urol Oncol,2011,29(3):259-264.
[6]	Cookson MS,Chang SS,Wells N,et al.Complications of radical cystectomy for nonmuscle invasive disease:comparison with muscle invasive disease[J].J Urol,2003,169(1):101-104.
[7]	Kulkarni GS,Finelli A,Fleshner NE,et al.Optimal management of high-risk T1G3 bladder cancer:a decision analysis[J].PLoS Med,2007,4(9):e284.
[8]	Sessler DI.Thermoregulatory defense mechanisms[J].Crit Care Med,2009,37(7 Suppl):S203-S210.
[9]	Hildebrandt B,Wust P,Ahlers O,et al.The cellular and molecular basis of hyperthermia[J].Crit Rev Oncol Hematol,2002,43(1):33-56.
[10]	van der Heijden A G,Hulsbergen-Van DKC,Witjes J A.The influence of thermo-chemotherapy on bladder tumours:an immunohistochemical analysis[J].World J Urol,2007,25(3):303-308.
[11]	Paroni R,Salonia A,Lev A,et al.Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma[J].Br J Clin Pharmacol,2001,52(3):273-278.
[12]	Maffezzini M,Campodonico F,Canepa G,et al.Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer(EORTC)score risk of recurrence and progression[J].Cancer Chemother Pharmacol,2014,73(5):925-930.
[13]	Cheng CW,Chan SF,Chan LW,et al.15-year experience on intravesical therapy of T1G3 urinary bladder cancer:a conservative approach[J].Jpn J Clin Oncol,2004,34(4):202-205.
[14]	Margel D,Tal R,Golan S,et al.Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy[J].Urology,2007,69(1):78-82.
[15]	Yk Z,Hb S,JQ,et al.Effect of combined administration of hydroxycamptothecin and pirarubicin in human bladder cancer cell line 5637[J].J Clin Urol,2008,23:617-629.
[16]	Gontero P,Sylvester R,Pisano F,et al.Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin:results of a retrospective multicenter study of 2451 patients[J].Eur Urol,2015,67(1):74-82.